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Abstract: A major hallmark of Alzheimer’s disease (AD) is the accumulation and deposition of
fibrillar aggregates of the amyloid- (A) peptide into neuritic plaques. These amyloid deposits
were thought to play a central role in AD; however, the correlation between plaque load and disease
is weak. Increasing evidence supports the notion that a variety of small, globular aggregates of A,
referred to broadly as A oligomers (AO), may in fact be the primary culprits associated with
neurotoxicity. Evaluation of AO structure and physiological activity is complicated by their
metastability, heterogeneity, complex aggregation pathways, and dependence on experimental
conditions. Numerous different types of oligomers have been reported, and these have been
associated with varying degrees of toxicity and modes of interaction. Here, we briefly review AOs
with a focus on their formation, structure, and biophysical methods applied to their investigation.
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1.

Introduction

Alzheimer’s disease (AD) is a fatal neurodegenerative disorder that is the most prevalent form
of dementia. The neuropathological and neurochemical hallmarks of AD include: Synaptic loss and
selective neuronal cell death; decreases in markers for certain neurotransmitters; and abnormalities in
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neurons and their processes as well as in the extracellular space. Two of the main features associated
with AD are neurofibrillary tangles comprised of the protein tau and cerebrovascular, diffuse, and
neuritic plaques composed predominantly of the amyloidogenic peptide amyloid-β (Aβ). These
proteinaceous deposits of tau and A consist of stable amyloid fibrils, which are -sheet rich fibrous
protein aggregates. Similar deposition of amyloid is associated with numerous other diseases [1].
In the early 90’s, the amyloid cascade hypothesis was introduced, which postulated that Aβ
aggregation and deposition directly lead to neuronal death, resulting in AD [2]. Yet, the correlation
between plaques and cognitive dysfunction in AD has been questionable for years [3–7], and with
Aβ-directed therapeutic strategies failing in numerous clinical trials, the role of A in AD
progression is being re-evaluated [8–11]. This has led to an enhanced research focus on diffuse,
soluble aggregates of Aβ. Various small, globular aggregates of A, referred to broadly as A
oligomers (AO), were detected in AD patients a few decades ago [12–14], and these AO were
originally classified as being intermediates toward the formation of amyloid fibrils. Over the years,
increasing evidence points toward AOs playing a central role in AD, as AOs correlate more
strongly with AD progression in patients and animal models [15–19]. For example, AO formation
and buildup occurs early compared with plaque buildup (much earlier than plaque deposition) in the
AD brain [20–22]and CSF [23], which has led to extensive efforts to develop assays to detect AOs
for potential application as biomarkers [24–31].
An extensive body of evidence has linked high levels of AOs in the brain to a variety of
pathogenic consequences associated with AD (summarized in Table 1). As such, there has been
significant effort made to characterize AβO formation, structure, and biochemical/biophysical
characteristics (such as interactions with other proteins and lipids) in the hope that underlying modes
of AβO-related toxicity could be revealed [32–37]. As AβOs are metastable, highly heterogeneous
in nature, and can form via a variety of different pathways, this remains a challenging task, yet
progress has been made. Here, we review AβOs with a focus on biophysical characterization of their
formation and structure.
Table 1. Toxic mechanisms associated with AβOs.
Toxic effects of AβOs
Reduction in neural plasticity
Stimulation of tau phosphorylation
Choline acetyltransferase Inhibition
Oxidative stress
Endoplasmic reticulum stress
Receptor disturbance
Insulin resistance
Synapse deterioration
Axonal transport
Astrocytes/microglia effects
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Model system(s)
References
mice, rat
[37–40]
cortical neurons (rat), hippocampal neurons,
[41–45]
neuroblastoma, primary neurons, Tg-Mice
cholinergic cell lines
[46,47]
cortical neurons, hippocampal neurons, in vitro,
[48–51]
neuroblastoma
cortical astrocytes, cortical neurons (rat),
[43,52,53]
fibroblasts, Tg-mice
cortical neurons, hippocampal neurons
[54–57]
cortical neurons, hippocampal neurons, rat
[40,42,57,58]
hippocampal neurons, pyramidal neurons (rat),
[21,35,54,59]
Tg-mice
cortical neurons, hippocampal, in vitro, Tg-mice
[60–62]
cortical astrocytes, Tg-mice
[44,52,63,64]
Continued on next page
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Toxic effects of AβOs
Cell cycle disruption
Selective neuron death
Inhibition of long-term potentiation
Calcium dysregulation
Modulation of metal toxicity
Cytoskeleton disruption
Modulation of Receptor/Channel
Activity

2.

Model system(s)
cortical neurons, Tg-mice
Mice
Mice
cortical neurons (rat), hippocampal neurons,
primary neurons
neuroblastoma
primary neurons
hippocampal neurons

References
[65,66]
[38,67]
[37,40]
[43,45,48,52]
[49]
[50]
[48]

The Aβ Peptide

Aβ is an approximately 4 kDA peptide (typically 40–42 amino acids long) that is derived from
the transmembrane portion of the amyloid precursor protein (APP; Figure 1). The production of Aβ
is achieved by the sequential cleavage of APP by two membrane-bound endoprotease activities, βand γ-secretase. The two predominant Aβ peptides produced are 40 and 42 amino acids in length, and
these peptides are referred to as Aβ40 and Aβ42 respectively. Aβ is amphipathic in nature (having a
predominately hydrophilic N-terminus and a predominately hydrophobic C-terminus), which is
thought to drive its aggregation. As the C-terminal end of Aβ coincides with the transmembrane
portion of APP, Aβ42 has a larger hydrophobic domain, making it more fibrillogenic compared to
Aβ40 and deposits to a much greater extent in the brain [68–70]. Only about 10% of APP is processed
via this Aβ producing pathway. Most APP is cleaved by the α-secretase, generating a series of much
more benign peptide fragments.
The hydrophilic N-terminal region of Aβ can adopt both an α-helical or β-sheet structure
dependent on solution conditions, for example pH [71,72]. The hydrophobic C-terminal end of Aβ
has a propensity to adopt β-sheet structure upon aggregation independent of solvent conditions [71,72].
Beyond its amphipathic nature, several other domains have been identified in Aβ. The different
polyomorphic fibril structures of Aβ are comprised of bundled β-sheets with backbones orthogonal to
the fiber axis creating a cross-β structure [73], and two β-strand forming domains (residues 11–21
and 29–39 respectively) that are separated by a turn/bend region (around residues 23–26) identified
through various experimental and computational studies [74–77]. The central region of Aβ (residues 16–21),
contained within one of the β-strands, has enhanced amyloidogenic properties and represents a
hydrophobic core [78].
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Figure 1. APP processing and subsequent Aβ amino acid sequence with specific domains
of interest specified. Proteolytic cleavage of APP is initiated at residue 671 by β-secretase
followed by either non-amyloidogenic processing, cleavage at residue 687 by α-secretase,
or amyloidogenic processing, cleavage at residue 711, 713, 714, or 726 by γ- secretase.
The amino acid sequence below highlights the region of APP from which A is produced
with the numbering referring the residues in A. The orange highlighted region
represents the intact Aβ42 sequence. Hydropathy indexes of individual residues are color
coded according to hydrophobic (blue), slightly hydrophobic (light green), and
hydrophilic (red). Regions of interest and cites of secretase activity within the APP and
A are indicated.
3.

Aβ aggregation—a complex mechanism

The aggregation of Aβ (and other amyloid-forming proteins) is typically characterized in terms
of fibril formation (Figure 2). Aβ fibril formation occurs via a complex aggregation pathway.
Fundamentally, AβOs can be subdivided into species that are intermediates in fibrils formation (referred
to as being on pathway) or species that do not directly lead to fibrils (referred to as being off
pathway). This is a contributing factor to the immense heterogeneity observed in AβO populations as
will be discussed in more detail later. In general, amyloid formation proceeds via a nucleation
dependent polymerization mechanism [79–81]. With this mechanism, aggregation initially occurs via
a slow nucleation phase (often called the lag phase) that involves the formation of a
thermodynamically unfavorable critical nucleus that is associated with a transition from a native to
non-native protein conformation. For Aβ, the critical nucleus is likely a multimeric species [82–84].
Once the critical nucleus has formed, an elongation or growth phase (characterized by a relatively
rapid extension of fibril aggregates) occurs. While numerical models can extract important
parameters (lag phase times, elongation rates, critical nucleus size) from experimental data [85], the
actual aggregation pathway toward fibrils can be complicated. For example, other on pathway
intermediates, like protofibrils, are also observed in Aβ aggregation. Protofibrils are amyloid-like,
elongated aggregates with filament-like morphologies and are late-stage intermediate precursors on
AIMS Biophysics
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the aggregation pathway to fibrils. A key aspect that facilitates on and off pathway aggregation routes
and complicates investigations of AβOs is that they possess structural plasticity and are metastable
and transient in nature.

Figure 2. Production and aggregation Aβ. Aβ is a cleavage product of APP, a
transmembrane protein. Monomeric Aβ transitions between ordered and disordered states.
Once dimerization occurs, subsequent aggregation occurs either on pathway or off
pathway with respect to fibril formation. The aggregates associated with these different
pathways increase in molecular weight from the left to the right of the schematic.
Fibrillization can proceed via several potential pathways that can populate various
intermediate aggregate states, including oligomers and protofibrils. Off-pathway
oligomers of various size may also form. Annular aggregates of Aβ can also form and are
thought to potentially be associated with forming pore-like structures.
Further complicating the issue is the observation that A can aggregate into a variety of
morphologically distinct fibril structures, referred to as polymorphs [86–90]. This phenomenon is
predicated on subtle changes of environmental conditions associated with aggregation, and as a result,
preparatory protocols employed in experiments determines the resulting A fibril morphology [87].
While polymorphic aggregates are readily observed with in vitro studies using synthetic Aβ,
polymorphic structures have been observed in amyloids derived from tissue, and it is thought that
variations in A aggregate morphologies may play an important role in AD [91,92]. For example,
polymorphic aggregates and fibrils may result in distinct biological activities and levels of toxicity
that could underlie variations in AD [76], and distinct fibril structures can be directly associated with
individual AD patients and clinical phenotype [93,94].
A complicating factor in evaluating and comparing studies aimed at elucidating AβO formation,
structure, and physiological impact is divergent experimental conditions, such as Aβ preparation
protocols, heavily influences experimental outcomes. In terms of oligomers, the emergence of
distinct fibril structure strongly suggests that there would also be distinct oligomeric precursors
AIMS Biophysics
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associated with their formation. Indeed, distinct AβO species can be observed within in vitro
aggregation assays under conditions that result in fibril polymorphs [95] (Figure 3). For studies
conducted with synthetic peptide, there are a variety of protocols used to solubilize A (Table 2).
Typically, these protocols consist of a disaggregation step and a reconstitution step. The
disaggregation steps usually involves the use of hydrogen bond disrupting solvents, i.e.,
hexafluoroisopropanol (HFIP) or trifluoroacetic acid (TFA), that break down pre-existing aggregates
within lyophilized stocks of A. These solvents are often removed under vacuum, leaving a peptide
film. The reconstitution step involves dissolving these peptide films into a solvent that facilitates
dilution into an appropriate buffer. Dimethyl sulfoxide (DMSO) is often used, creating a
concentrated stock that is diluted into the desired buffer. Disaggregation and reconstitution can also
be facilitated by changes in pH. Sometimes reconstitution is performed directly into the final buffer.
Importantly, variations in preparatory protocols indeed result in different populations of oligomers (Table 2
and Figure 3), and these variations can complicate direct comparisons between different reports
within the literature. Further complicating the issue, there are often distinctions observed between
studies performed with synthetic A and naturally derived A [96]. In many studies aimed at
elucidating activity of AβOs, specific preparations are used to obtain a particular population of
oligomer species. These are then directly applied to different model systems, ranging from cell
culture to animal models. However, there is often a lack of effort to verify that once added to the
model system (which can often be a pronounced change in chemical environment) that these AβO
species do not dissociate or aggregate into a different AβO or Aβ aggregate. To truly relate specific
AβOs to a neurotoxic activity, effort should be invoked to attempt additional controls of this type.
Table 2. Representative disaggregation, reconstitution, and miscellaneous protocols for
the preparation of Aβ and observed AβOs.
Classification

Disaggregation

Reconstitution

ADDLs

None

F12 Media 4 ℃

ADDLs

HFIP

Globulomers

HFIP

Globulomers

HFIP

Miscellaneous

Result

References

Centrifuged 14,000 ×g for

5–6 nm by AFM

10 mins

(height)

DMSO at 5 mM

Sonicate 5 mins, dilute with

Aβ

DMEM/F12 Media

DMSO at 5 mM

Sonicate 10 mins, dilute

16–56 kDa by

Aβ

PBS + 0.05% SDS

SDS-PAGE

DMSO at 5 mM

Dilute PBS + 0.05% SDS,

38–48 kDa by

Aβ

Dialyze

SDS-PAGE

A11+

[38]
[97]
[98]
[99]

Sonicate 20 min, PBS +
Aβ*56

HFIP

DMSO at 5 mM

0.2% SDS incubate 6 h,

56 kDa by

Aβ

dilute and incubated 18 h;

Native-PAGE

[100]

centrifuge 3000 ×g, dialysis
AβOs

HFIP

AβOs

HFIP/NH4OH

AβOs

TFA/HFIP (2Xs)

DMSO
10 mM
Tris-HCl
2 mM NaOH

F12 Media incubated at
4 ℃ for 24 h
Addition of Zn2+
PBS Centrifuge 386,000 ×g

1–4 nm by AFM
10–12 nm by
AFM
2.5 nm by AFM

[101,102]
[97]
[87,95]

Continued on next page
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Classification

Disaggregation

Reconstitution

Miscellaneous

PBS

-

60 mM NaOH

-

TFA salt/2 mM
AβOs

NaOH, pH ~10.5,
1 min sonication
10% NH4OH

AβOs

(w/v) sonicated 5
mins, lyophilized

Sonicate 1 min, centrifuge
AβOs LMW

-

DMSO

16,000 ×g, SEC, PBS,
PICUP crosslinking

Result

References

3–12 nm by
AFM
1–10 nm by
DLS
4–26 kDa by
SDS-PAGE

[103]

[104]

[105]

Figure 3. Heterogeneity of AβOs. A series of atomic force microscopy images and size
analysis, i.e. height histograms, of AβOs formed from synthetic Aβ that had been
prepared by some of the protocols described in Table 2. The AβOs were prepared in the
following way: (A) protocol provided in the AggreSure β-amyloid kits available from
AnaSpec which consists of a reconstitution step directly into Tris buffer with bath
sonication; (B) 10% NH4OH disaggregation buffer, followed by additional treatment
with HFIP, and reconstitution in 2 mM NaOH (pH > 11) with subsequent dilution into
Tris buffer; (C) 10% NH4OH disaggregation buffer, and reconstitution in 60 mM
NaOH (pH > 11) with subsequent dilution into HEPES buffer; (D) HFIP disaggregation,
reconstitution in DMSO, followed by dilution into PBS; (E) TFA disaggregation with
sonication, an additional HFIP disaggregation step, reconstitution with NaOH, and dilution
into PBS; (F) No disaggregation step and direct reconstitution in to phosphate buffer.

AIMS Biophysics
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4.

Classifying AβOs

Enormous efforts have been extended in identifying the most toxic/disease-relevant AO species
and the relevant underlying structure [9,106,107]. This is a daunting endeavor due to the transient
nature and extensive heterogeneity associated with AOs [108–110]. It is possible that different AβO
species may activate different deleterious changes associated with AD [9,106,107]; however, there
may also be relatively benign AO species or even experimental artifacts [96,108,111]. Unraveling the
physiological activity of AβOs may require separate analysis of these different species, which may
be altered by preparatory protocols. The ability of smaller AβO (like dimers and trimers) to further
aggregate into large, more stable synaptotoxic assemblies [107] must be accounted for in assessing
the toxic effects of specific AβO species. That is, upon the addition of preparations of AβO to cell
culture or other models, AβOs may further assemble into other higher order species that may
influence the associated toxic effects. Despite the inherent complexity of this endeavor, progress has
been made. Aβ trimers have been linked to playing a role in inducing pathological conformational
changes in tau [112]. However, crosslinked Aβ dimers were shown not to be toxic themselves, but
rather contributed to toxicity by further assembling into larger assemblies [113]. A 56 kDa
SDS-stable Aβ0 (referred to as Aβ*56) has been identified as a prominent specie in the AD brain [16],
CSF [22], and in transgenic mouse models of AD [32,114]. In terms of an actual biological activity,
Aβ*56 interacts with N-methyl-D-aspartate receptors (NMDARs), increasing NMDAR-dependent
Ca2+ influx and activation of Ca2+/calmodulin-dependent kinase IIα (CAMKIIα) [115]. Activation of
CAMKIIα correlates with enhanced site-specific phosphorylation and mis-sorting of tau [115].
Smaller AβOs, namely dimers and trimers, do not appear to elicit these specific effects.
There appears to be some common themes emerging with respect to toxicity. Toxic AβOs appear
to react with oligomer specific antibodies like A11 (generic for amyloid oligomers in general, [116])
and NU4 (specific for AβOs) [117]; whereas, nontoxic AβOs demonstrate reactivity with anti-fibril
antibodies like OC [116]. Importantly, toxic AβOs appear to be unrelated to plaques [116,118]. AβOs
related to amyloid plaques temporally, spatially, and structurally are nontoxic [118]. A number of
toxic AβO species are larger than 50 kDa [21,54,118], like the previously mentioned Aβ*56 [32].
Smaller AβOs appear to be less toxic or even benign [21,54,118,119], except for their ability to
further aggregated into larger assemblies. This has led to distinguishing between high molecular
weight (HMW) and low molecular weight (LMW) oligomers [120]. Aggregation mechanisms
differentiating between the eventual formation of HMW and LMW AβOs already appear to deviate at
the dimer stage [121]. Furthermore, LMW and HMW Aβ oligomers differentially impact synapses
and memory [122,123]; although, LMW AβOs are not always associated with memory
dysfunction [116,117]. HMW AβOs are the predominant Aβ species in the native soluble protein
fraction of AD brains [124]. These HMW species in the AD brain sometimes appear to be
constructed from smaller ~7 kDa Aβ species [125]. Neurohistopathological and biochemical analyses
of AβOs in the temporal cortex of AD brains implicated an Aβ dodecamer (~55 kDa) [126]. HMW
AβOs bind cultured synapses [21,54,118], induce reactive oxygen species (ROS) production [123],
and disrupt memory function [116,117]. With respect to the previously defined aggregation pathways,
LMW AβOs are typically on pathway to fibril formation; HMW AβOs are off-pathway [127,128].
This is consistent with HMW AβOs being potent, as off pathway AβOs appear more toxic [129].
Collectively, these observations point to the complex interplay between different AO species and
their specific activity with respect to neurotoxicity.
AIMS Biophysics
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Table 3. Methods used for analyzing AβOs.
Technique

Features of AβOs Obtained

Atomic Force Microscopy (AFM)

Morphology, population distributions

Electron Microscopy (EM)

Morphology, population distributions

Ion-Mobility Mass Spectroscopy (IM-MS)

Secondary structure, multimeric configurations

Nuclear Magnetic Resonance 2D (NMR)

Secondary structure, multimeric configurations, atomic resolution structure

Electron Paramagnetic Resonance (EPR)

Secondary structure, multimeric configurations, atomic resolution structure

Powder X-ray Diffraction (PXRD)

Atomic resolution structure

Small Angle X-ray Scattering (SAXS)

Atomic resolution structure

Single Crystal X-ray Diffraction (SCXD)

Atomic resolution structure

SDS-Page

Size distribution of multimers

5.

Characterizing AβO structure and activity

To facilitate structure/activity analysis, significant efforts have been made to obtain structural
details of AβOs using a variety of methods (Table 3). This is required to fully elucidate the modes of
interaction of AβOs with other biomolecules and related toxic mechanisms [32,33,35–37,130].
Structural characterization of specific AOs is challenging due to their transient nature and
heterogeneity. AβOs can exhibit conformational plasticity that can be heavily influenced by
environmental factors, further complicating such analysis. Despite these inherent challenges, efforts
have been made to separate, isolate, and characterize distinct AβO species obtained from synthetic
Aβ or from AD brain tissue and cell cultures [18,32,35–37,114,129,131–136]. With regard to HMW
and LMW AβOs, they are separable in vitro by size exclusion chromatography [137] or ultrafiltration
with a 50 kDa molecular weight cutoff [21,54,118]. Quick characterization of AOs can be
accomplished by chromatographic techniques, SDS PAGE, and by the use of a variety of oligomer
specific antibodies (Table 4).
Table 4. Anti-AβO specific antibodies.
Antibody

Epitope

References

A11

Soluble amyloid oligomers

[17,138]

NAB61

Dimeric, oligomeric, higher order aggregates

[139]

NU-1

ADDLs specific

[140]

NU-2

ADDLs weak binding; no Aβ monomer staining

[140]

NU-4

ADDL trimer, tetramer, and 12–24 mer specific

[140]

One strategy that has been used to overcome obstacles associated with characterizing AOs has
been to stabilize oligomers via cross-linking. Such methods can lead to not only structural but also
functional characterization of AOs. Photo-induced crosslinking (PICUP) was initially used to
stabilize and characterize LMW AOs of A40 and A42 [33,141–143].While A40 primarily formed
an equilibrium of dimers, trimers, and tetramers, A42 aggregated into pentamers/hexamers that
further assembled into protofibrils [143]. Using mutated A42 (F10, Y42), AOs ranging from dimer
to dodecamers were stabilized using PICUP [141], opening up the ability to perform structure/activity
analysis on AOs up to 50 kDa in size. AOs can also be stabilized using dityrosine crosslinking,
AIMS Biophysics

Volume 6, Issue 1, 1–22.

10

which occurs under elevated copper concentrations and oxidative stress [144]. Both of these
conditions have been linked to AD, suggesting that the crosslinking associated with this method may
be more physiologically relevant [145,146]. In fact, dityrosine crosslinked proteins are observed in
amyloid plaques and CSF from AD patients [145]. Dityrosine linkages are associated with
copper-mediated stabilization of AOs [147]. Copper stabilization is effective enough to allow for
3D structural characterization of AOs by small-angle x-ray scattering [148], and the copper to A
ratio could push aggregation toward ellipsoidal oligomers of 38 peptides (excess copper) or
fibrils (excess A) [119].
Another method to overcome the metastability of Aβ species and control the aggregation
process is to complex/fuse Aβ sequences within other protein. Aβ sequences are often based on
previously identified regions of the peptide that have been identified as playing a role in Aβ
aggregation (Figure 1). Such a strategy has been successful in studying monomeric structure of Aβ
sequences [149]. With careful design, this method has been applied to stabilizing oligomers derived
from Aβ fragments for structural characterization. Fusion of Aβ18–41 with the CDR3 loop region of a
shark Ig new antigen receptor single variable domain antibody resulted in the formation and
stabilization of tightly associated Aβ dimers, which could pair to form tetramers [150]. This dimer
had a compact structure rather than a β-turn/β-sheet structure. Several engineered peptide
macrocycles that incorporate Aβ sequences (Aβ15–23 and Aβ17–36) have been designed to contain
aggregation to the oligomeric state, and these systems have been structurally characterized by X-ray
crystallography and NMR spectroscopy [151–153]. Collectively, this macrocycle strategy has
revealed numerous dimers, trimers, tetramers, and higher order oligomer species that display a
variety of β-sheet based structural heterogeneity.
Due to the complex nature of Aβ aggregation, techniques that allow for distinguishing and
characterizing distinct morphological features of AβOs within heterogeneous aggregation reactions
are of enormous benefit. Both atomic force microscopy (AFM) and electron microscopy (EM)
provide this capability. In particular, AFM has emerged as a particularly useful technique in studying
AβO formation and morphology [95,101,134,135,154–160]. As AFM can be operated in solution, it
has the ability to observe and track the behavior of individual AβOs on surfaces under physiological
buffer conditions [158,160]. The surfaces used in AFM experiments have become progressively
more biologically relevant and include lipid membranes [135,161–164]. With regard to Aβ
aggregation on lipid membranes, in solution AFM studies have demonstrated the formation of
distinct oligomeric aggregates associated with point mutation in Aβ [165], the formation of pore-like
AβO morphologies [154–156], that preparation history influences AβO formation on bilayers [95],
and that mechanical changes occur in bilayers associated with the presence of AβOs [166]. AFM
based force spectroscopy has even been used to understand the energetics of AβO formation and
stability [167,168].
With the recent development of high-speed AFM in solution, insights into the dynamics and fate
of individual AβOs has been achieved [128,169]. Using high-speed AFM to track the dynamics of
PICUP-stabilized LMW AβOs demonstrated that these AβOs were highly dynamic in structure,
fluctuating between single and multi-globular assemblies [169]. Direct visualization of Aβ
aggregation with high-speed AFM imaging demonstrates that LMW AβOs much more quickly
transition to form fibrils with distinct morphologies compared with HMW AβOs [128]. Despite being
classified as being off-pathway, HMW AβOs can still contribute to fibril formation by serving as a
reservoir of Aβ. That is, HMW AβOs may dissociate into smaller LMW AβO that seed
AIMS Biophysics
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fibrillization [128]. This again points to the necessity to track the fate of AβO species when
evaluating their physiological activities. For example, the LMW AβOs that are dissociation products
of HMW AβOs may actually be more toxic [170].
Another technique that is capable of characterizing heterogeneous populations of AβOs is ion
mobility mass spectrometry (IM-MS). These IM-MS studies ascertained qualitative differences in AβO
structure associated with Aβ40 and Aβ42 [131,132]. Aβ40 tetramers displayed an enclosed ring-shaped
configuration that would inhibit additional contacts required to assemble into larger AβO species [131,132].
Aβ42 tetramers preferentially had a bent structure that would provide oligomer ends capable of
additional contacts and enabling further aggregation. Indeed, Aβ42 was capable of forming larger
donut-shaped dodecamers.
Another strategy to perform structural analysis of AβOs is utilizing specific conditions to stabilize
them via a kinetic trap. Such an approach has been successfully used to enable NMR spectroscopy of
AβOs [171,172]. By incubation of Aβ at 4 ℃ and freeze-trapping with liquid nitrogen, heterogeneous,
spherical AβOs were analyzed with 2D NMR and shown to possess in-register parallel β-strand structure
similar to fibrils [172]. Based on NMR analysis, Aβ42 pentamers stabilized at a low 4 ℃ and 10 mM salt
concentration were disordered [171]. These Aβ42 pentamers displayed enhanced toxicity compared with
protofibrils or fibrils [171]. An atomic model of Aβ42 oligomers consisting of approximately 15–24
peptides has been proposed from a combination of biophysical techniques [173]. These oligomers
were prepared by disaggregation in HFIP followed by resuspension in dilute ammonium hydroxide,
preventing fibril formation. These were not end-stage AβOs, as subsequent dilution in PBS resulted
in fibril formation. Powder X-ray diffraction patterns of the AβOs were consistent with helical
β-sheet pairs wrapped together into a super-helix. This wrapping results in a hole along the
super-helix axis, which is consistent with proposed toxic mechanisms in which Aβ forms pathogenic
pores. Another proposed structure, based on site-directed spin labeling and electron paramagnetic
resonance, shares similarities with this structure [174]. This study used Aβ42 fused to
GroES-ubiquitin that formed stable oligomers that were A11 positive. Based on the EPR data, an
AβO model was proposed that consisted of a β-sheet with three antiparallel strands with these strands
being arranged head to tail. These sheets are further packed face to back as a group of four.
Even just tracking AβO formation has been challenging. A number of straight forward
spectroscopic assays are well-established to track formation and kinetic parameters of fibrils (e.g.,
ThT), but methods to easily track AO formation have been lacking. Recently, the use of
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) dyes have been utilized to fluorescently
detect the AOs in vitro [175,176]. These BODIPY fluorescent probes have high quantum yields
with the capability of selectively binding to AβOs [177]. Importantly, increases and decreases in
the “BD-Oligo” dye fluorescence also correlated with increasing and decreasing intensities of A11
staining, directly relating this signal to an established methods to detect AOs [175]. In addition, the
BD-Oligo dye can be used in parallel with ThT assays that detect fibril formation, allowing for the
direct investigation of the correlation between oligomer and fibril formation [175]. A BODIPY-based
probe (BAP-1) has also facilitated the direct visualization of Aβ plaques in transgenic mice [177],
and rational modifications of BAP-1 also allowed for near-infrared selective detection of tau
neurofibrillary tangles [178]. The ability to rationally modify BODIPY dyes for fluorescent detection
of specific aggregate species, the tunability of their spectroscopic properties, and their insensitivity to
solvent and pH changes have made BODIPY dyes a recently promising avenue for high throughput
studies of AβO formation and stability.
AIMS Biophysics
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6.

Conclusion

While the aggregation of Aβ has been extensively studied, there is still much to understand at
the molecular level about AβO formation, structure, and activity. Due to the transient nature of AβOs,
their morphological heterogeneity, and the continuing debate concerning specific toxic aggregate
species associated with AD, structural details and physiological activities of the variety of AβOs still
need to be fully elucidated. The exact mechanisms associated of how AβOs lead to cellular
dysfunction and death have not fully been explained. Understanding these phenomenon may prove
crucial in the effectiveness of therapeutic strategies based on manipulating Aβ production, clearance,
and aggregation. Here, we highlighted some specific features of AβOs and techniques that have
provided insight into their structure and formation. While this review is far from exhaustive, we hope
that collectively they provide a compelling argument toward the importance of understanding the
nature of AβOs, highlight some of the intrinsic obstacles associated with studying AβOs, and provide
some insight into methods that will play a role in pushing our knowledge of AβOs further.
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